



## **Access to Medicine Policy**

**Telix Pharmaceuticals Limited**  
**ACN 616 620 369**

Adopted by the Board on 13 December 2022

## 1. Introduction

---

### 1.1 Statement of intent

Telix Pharmaceuticals Limited (the **Company**) and its related bodies corporate (together, the **Group**) is changing the way we find and treat cancer and rare diseases. Our products use targeted radiation to image disease and deliver personalised therapy in areas of significant unmet medical need. At our core, we exist to create products that seek to extend and improve the quality of life by enhancing the use of radiation in cancer care from diagnostics and staging, to therapy and surgical intervention.

Telix believesunderstands that access to quality-assured medical products improves health and saves lives. We acknowledge that access to health products is uneven across the globe, and that one third of the world does not have adequate access to essential medicines<sup>1</sup> and treatments.

Telix's philosophy on access to medicine complements and aligns with Telix Group values, mission and vision, as well as the principles set out in the Group's Code of Conduct.

### 1.2 Scope

At the date of this policy, Telix has twoone products commercially approved in certain jurisdictions - bothan imaging agents for men with prostate cancer - and a pipeline of innovative diagnostic and therapeutic assets under development.

Given the Group's current size and stage, setting defined targets with respect to access to medicine strategies is not appropriate. The Group will continue to assess this status year-on-year.

### 1.3 Statement of guiding principles and commitments

In line with our philosophy and values, with respect to access to medicine, Telix is committed to:

- discovery and innovation;
- enabling access where possible and incorporating compliant access strategies into our product development, post-clinical trial and lifecycle management plans and strategies;
- working with industry partners and patient advocacy groups where possible with the aim of reaching more people with more products; and
- promotion of strong global healthcare systems.

## 2. Commitment to discovery and innovation

---

The development and timely access to new and better medicines requires strong innovation.

Telix's values affirm our commitment to explore possibilities, embrace challenge and use our talents and knowledge to create a better future for the patients whom we collectively serve. Telix is harnessing the power of targeted radiation to develop new products, complement existing therapies and explore new clinical applications. Telix's aim is to build a pipeline of new product candidates and related platform technologies that can dramatically improve patient outcomes.

Telix has a strong research and developmentinnovation program with a strategic scope to not only develop new medical products but also develop ways to make existing medical products better and / or more accessible to patients across the globe with unmet medical needs.

## 3. Commitment to enabling access and incorporating access strategies into development plans

---

Telix is committed to developing innovative products and treatments for cancer and rare diseases. Some people living with cancer and / or rare disease may wish to access investigational medicines that are not yet approved by the U.S. Food and Drug Administration, European Medicines Agency, or other regulatory authoritiesbody.

In general, Telix believes that participating in clinical trials conducted under International Conference on Harmonisation guidelines for Good Clinical Practice (ICH GCP) standards with full local regulatory and human research ethics committee (HREC) review is the most appropriate way for patients to access medicines prior to

---

<sup>1</sup> <https://msf.org.uk/>

regulatory approval and marketing authorization. In some circumstances when this is not possible, patients with life-threatening conditions may seek special or compassionate access to Telex's investigational medicines outside of a formal clinical trial setting. These situations are typically referred to as compassionate use, but can also be known as expanded access, special license, special access, early access, pre-approval access and emergency use. The criteria for these options are based on regulations enabling this type of access that are different in each country.

~~In a~~ Additionally, such programmes may be a condition of specific regulatory pathways such as Expanded Access Programmes with Breakthrough Designation from the FDA.

Telex will consider compassionate use requests from treating physicians subject to relevant local / national laws and regulations, and Telex's relevant policies and procedures. ~~Receipt of a request will be acknowledged within three (3) business days.~~

At the stage where clinical trials have successfully completed and the Group is planning to apply for marketing authorisations, Telex will develop post-clinical trial and lifecycle management plans and strategies. In the development of these plans and strategies, Telex will seek to incorporate relevant access strategies.

#### **4. Commitment to working with industry partners and patient advocacy groups**

---

Telex will maintain an awareness of the efforts and strategic plans of industry partners - including large pharmaceutical companies, supply chain partners and government or non-government agencies ~~—~~ and patient advocacy groups on access to medicine issues. Where possible and aligned to the Group's strategic objectives, mission and values, Telex will work with industry partners to consolidate efforts and positive outcomes for more patients.

#### **5. Promotion of strong global healthcare systems**

---

Telex recognises that industry plays a key role in developing and proving new medicines and treatments to address unmet needs. Telex supports the view that governments are primarily responsible for establishing effective, functioning, accessible healthcare systems.

Without healthcare systems that can ensure affordability and sustainability for patients and other stakeholders, the efficacy of individual access to medicine strategies will typically be limited.

We support the view that is a shared responsibility of all global healthcare stakeholders to help address the rising gap between those with access to critical healthcare and those without.

#### **6. Governance and Policy Review**

---

This Policy has been approved by the Board of Telex Pharmaceuticals Limited.

The Company will annually review this Policy and restate its commitments to access to medicine principles.



## **Access to Medicine Policy**

**Telix Pharmaceuticals Limited**  
**ACN 616 620 369**

Adopted by the Board on 19 May 2026

## 1. Introduction

---

### 1.1 Statement of intent

Telix Pharmaceuticals Limited (the **Company**) and its related bodies corporate (together, the **Group**) is changing the way we find and treat cancer and rare diseases. Our products use targeted radiation to image disease and deliver personalised therapy in areas of significant unmet medical need. At our core, we exist to create products that seek to extend and improve the quality of life by enhancing the use of radiation in cancer care from diagnostics and staging, to therapy and surgical intervention.

Telix believes that access to quality-assured medical products improves health and saves lives. We acknowledge that access to health products is uneven across the globe, and that one third of the world does not have adequate access to essential medicines<sup>1</sup> and treatments.

Telix's philosophy on access to medicine complements and aligns with Telix Group values, mission and vision, as well as the principles set out in the Group's Code of Conduct.

### 1.2 Scope

At the date of this policy, Telix has two products commercially approved in certain jurisdictions - both imaging agents for men with prostate cancer - and a pipeline of innovative diagnostic and therapeutic assets under development.

Given the Group's current size and stage, setting defined targets with respect to access to medicine strategies is not appropriate. The Group will continue to assess this status year-on-year.

### 1.3 Statement of guiding principles and commitments

In line with our philosophy and values, with respect to access to medicine, Telix is committed to:

- discovery and innovation;
- enabling access where possible and incorporating compliant access strategies into our product development, post-clinical trial and lifecycle management plans and strategies;
- working with industry partners and patient advocacy groups where possible with the aim of reaching more people with more products; and
- promotion of strong global healthcare systems.

## 2. Commitment to discovery and innovation

---

The development and timely access to new and better medicines requires strong innovation.

Telix's values affirm our commitment to explore possibilities, embrace challenge and use our talents and knowledge to create a better future for the patients whom we collectively serve. Telix is harnessing the power of targeted radiation to develop new products, complement existing therapies and explore new clinical applications. Telix's aim is to build a pipeline of new product candidates and related platform technologies that can dramatically improve patient outcomes.

Telix has a strong research and development program with a strategic scope to not only develop new medical products but also develop ways to make existing medical products better and / or more accessible to patients across the globe with unmet medical needs.

## 3. Commitment to enabling access and incorporating access strategies into development plans

---

Telix is committed to developing innovative products and treatments for cancer and rare diseases. Some people living with cancer and / or rare disease may wish to access investigational medicines that are not yet approved by the U.S. Food and Drug Administration, European Medicines Agency, or other regulatory authorities.

In general, Telix believes that participating in clinical trials conducted under International Conference on Harmonisation guidelines for Good Clinical Practice (ICH GCP) standards with full local regulatory and human research ethics committee (HREC) review is the most appropriate way for patients to access medicines prior to

---

<sup>1</sup> <https://msf.org.uk/>

regulatory approval and marketing authorization. In some circumstances when this is not possible, patients with life-threatening conditions may seek special or compassionate access to Telix's investigational medicines outside of a formal clinical trial setting. These situations are typically referred to as compassionate use, but can also be known as expanded access, special license, special access, early access, pre-approval access and emergency use. The criteria for these options are based on regulations enabling this type of access that are different in each country.

Additionally, such programs may be a condition of specific regulatory pathways such as Expanded Access Programs with Breakthrough Designation from the FDA.

Telix will consider compassionate use requests from treating physicians subject to relevant local / national laws and regulations, and Telix's relevant policies and procedures.

At the stage where clinical trials have successfully completed and the Group is planning to apply for marketing authorisations, Telix will develop post-clinical trial and lifecycle management plans and strategies. In the development of these plans and strategies, Telix will seek to incorporate relevant access strategies.

#### **4. Commitment to working with industry partners and patient advocacy groups**

---

Telix will maintain an awareness of the efforts and strategic plans of industry partners including large pharmaceutical companies, supply chain partners and government or non-government agencies - and patient advocacy groups on access to medicine issues. Where possible and aligned to the Group's strategic objectives, mission and values, Telix will work with industry partners to consolidate efforts and positive outcomes for more patients.

#### **5. Promotion of strong global healthcare systems**

---

Telix recognises that industry plays a key role in developing and proving new medicines and treatments to address unmet needs. Telix supports the view that governments are primarily responsible for establishing effective, functioning, accessible healthcare systems.

Without healthcare systems that can ensure affordability and sustainability for patients and other stakeholders, the efficacy of individual access to medicine strategies will typically be limited.

We support the view that is a shared responsibility of all global healthcare stakeholders to help address the rising gap between those with access to critical healthcare and those without.

#### **6. Governance and Policy Review**

---

This Policy has been approved by the Board of Telix Pharmaceuticals Limited.

The Company will annually review this Policy and restate its commitments to access to medicine principles.